Literature DB >> 31098669

Which is Better for Patients with Breast Cancer: Totally Implanted Vascular Access Devices (TIVAD) or Peripherally Inserted Central Catheter (PICC)?

Tian-Tian Tang1, Lei Liu1, Chun-Xiao Li1, Yun-Tao Li1, Tao Zhou1, Hai-Ping Li1, Jianxin Wang2.   

Abstract

BACKGROUND: Our aim was to compare the applications of totally implanted vascular access devices (TIVAD) and peripherally inserted central catheter (PICC) in breast cancer patients.
METHODS: We analyzed 4080 cases of TIVAD and 1433 cases of PICC at the Breast Center of the Fourth Hospital of Hebei Medical University. The success rate, operation time, and procedures of catheterization, as well as the catheterization-related complications, catheter indwelling-related complications, and the utilization conditions were compared between these two methods.
RESULTS: Our results showed that the success rate of catheterization was relatively higher in PICC group (99.5%) than the TIVAD group (99.0%)(χ2 = 3.521, P = 0.038), and the operation time and the rate of catheterization-related complications were lower in PICC (18.65 ± 4.7603 min, 0.91%) compared to TIVAD (29.55 ± 4.0843 min, 1.59%)(t = 38.000, P < 0.01, χ2 = 3.578, P = 0.035). However, the rate of catheter indwelling-related complications was lower in TIVAD group (2.47%) than the PICC group (3.62%)(χ2 = 5.227, P = 0.016), and the catheter care was also better in TIVAD.
CONCLUSIONS: Based on these analyses, we recommended TIVAD for the patients who need long-term and high-dose chemotherapy and PICC for the patients who need short chemotherapy cycle and live close to the hospital.

Entities:  

Mesh:

Year:  2019        PMID: 31098669     DOI: 10.1007/s00268-019-05022-x

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  17 in total

1.  Comparison of peripherally inserted central venous catheters (PICC) versus subcutaneously implanted port-chamber catheters by complication and cost for patients receiving chemotherapy for non-haematological malignancies.

Authors:  G S Patel; K Jain; R Kumar; A H Strickland; L Pellegrini; J Slavotinek; M Eaton; W McLeay; T Price; M Ly; S Ullah; B Koczwara; G Kichenadasse; C S Karapetis
Journal:  Support Care Cancer       Date:  2013-09-05       Impact factor: 3.603

2.  Using the Theory of Planned Behavior to explore hospital-based nurses' intention to use peripherally inserted central catheter (PICC): a survey study.

Authors:  Laura Bertani; Maria Carone; Luca Caricati; Serena Demaria; Silvia Fantuzzi; Alessandro Guarasci; Luca Pirazzoli
Journal:  Acta Biomed       Date:  2016-11-22

3.  A silicone rubber atrial catheter for prolonged parenteral alimentation.

Authors:  J W Broviac; J J Cole; B H Scribner
Journal:  Surg Gynecol Obstet       Date:  1973-04

4.  The central vein access port and catheter in outpatient chemotherapy for colorectal cancer: a retrospective study of 101 patients.

Authors:  Hiroshi Sawayama; Naoko Hayashi; Masayuki Watanabe; Hiroshi Takamori; Toru Beppu; Hideo Baba
Journal:  Surg Today       Date:  2011-11-22       Impact factor: 2.549

5.  Reducing the risk of peripherally inserted central catheter line complications in the oncology setting.

Authors:  Y-S Yap; C Karapetis; S Lerose; S Iyer; B Koczwara
Journal:  Eur J Cancer Care (Engl)       Date:  2006-09       Impact factor: 2.520

6.  Complication rates among cancer patients with peripherally inserted central catheters.

Authors:  Louise J Walshe; Sharp F Malak; Janet Eagan; Kent A Sepkowitz
Journal:  J Clin Oncol       Date:  2002-08-01       Impact factor: 44.544

7.  Peripherally inserted central venous catheters for autologous blood progenitor cell transplantation in patients with haematological malignancies.

Authors:  C Harter; T Ostendorf; A Bach; G Egerer; H Goldschmidt; A D Ho
Journal:  Support Care Cancer       Date:  2003-09-20       Impact factor: 3.603

8.  Infective and thrombotic complications of central venous catheters in patients with hematological malignancy: prospective evaluation of nontunneled devices.

Authors:  Leon J Worth; John F Seymour; Monica A Slavin
Journal:  Support Care Cancer       Date:  2008-12-19       Impact factor: 3.603

9.  Morbidity of chemotherapy administration and satisfaction in breast cancer patients: a comparative study of totally implantable venous access device (TIVAD) versus peripheral venous access usage.

Authors:  Kul Ranjan Singh; Gaurav Agarwal; Gitika Nanda; Gyan Chand; Anjali Mishra; Amit Agarwal; Ashok K Verma; Saroj K Mishra; Puneet Goyal
Journal:  World J Surg       Date:  2014-05       Impact factor: 3.352

10.  An 11-year retrospective study of totally implanted central venous access ports: complications and patient satisfaction.

Authors:  A Ignatov; O Hoffman; B Smith; J Fahlke; B Peters; J Bischoff; S-D Costa
Journal:  Eur J Surg Oncol       Date:  2008-03-10       Impact factor: 4.424

View more
  4 in total

1.  Which is Better for Patients with Breast Cancer: Totally Implanted Vascular Access Devices (TIVAD) or Peripherally Inserted Central Catheter (PICC)?

Authors:  Adriana Toro; Elena Schembari; Edoardo Mattone; Isidoro Di Carlo
Journal:  World J Surg       Date:  2020-03       Impact factor: 3.352

Review 2.  Adult oncology patients' experiences of living with a central venous catheter: a systematic review and meta-synthesis.

Authors:  Dhurata Ivziku; Raffaella Gualandi; Francesca Pesce; Anna De Benedictis; Daniela Tartaglini
Journal:  Support Care Cancer       Date:  2022-01-14       Impact factor: 3.603

3.  Perioperative and Postoperative Complications of Supraclavicular, Ultrasound-Guided, Totally Implantable Venous Access Port via the Brachiocephalic Vein in Adult Patients: A Retrospective Multicentre Study.

Authors:  Zepeng Yu; Xingwei Sun; Xuming Bai; Wei Ding; WeiDong Wang; Liang Xu; Wenming Qin; Ling Wen; Yong Jin
Journal:  Ther Clin Risk Manag       Date:  2021-02-04       Impact factor: 2.423

4.  Tailored approach to the choice of long-term vascular access in breast cancer patients.

Authors:  Hyangkyoung Kim; Sukyung Kwon; Soo Mi Son; Eunseon Jeong; Jang-Yong Kim
Journal:  PLoS One       Date:  2021-07-22       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.